Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

GLP-1R agonist withdrawal effect on weight loss and cardiovascular risks remains unmet need, says GlobalData

Eli Lilly recently published the results of a Phase III trial investigating the maintenance of Zepbound’s weight loss effects in overweight and obesity patients. Zepbound is Eli Lilly’s new glucagon-like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) dual agonist, approved by the FDA in November 2023, showing great promise compared to the other GLP-1R agonists on the market. […]
Read more

Inflammatory bowel disease market risks contraction, says GlobalData

In recent years, the increase in inflammatory bowel disease (IBD) biologic treatments has been a major driving force in the growth of this market. In 2007, AbbVie’s Humira received approval from the FDA to treat moderate-severe Crohn’s disease (CD). Since then, the IBD market has seen the entry of seven biologics. With more biologics anticipated […]
Read more

Female contraceptives market across 7MM to see only slight growth over next 10 years, forecasts GlobalData

The female contraceptives market across the seven major markets (7MM*) is forecast to slightly increase at a compound annual growth rate (CAGR) of 0.5% from $7.8 billion in 2022 to $8.2 billion in 2032, according to GlobalData, a leading data and analytics company. GlobalData’s latest report “Female Contraceptives in Major Markets, Disease Management, Epidemiology, Pipeline […]
Read more

Positive Rezzayo data marks milestone in candidemia and invasive candidiasis treatment, says GlobalData

Melinta Therapeutics and Cidara Therapeutics released extensive data from two global clinical trials on their candidemia and invasive candidiasis drug Rezzayo (rezafungin acetate). The findings affirm the safety and efficacy of Rezzayo, a novel echinocandin antifungal administered through weekly intravenous (IV) infusion. This reinforces its market position, emphasizing its efficacy and safety in addressing fungal […]
Read more

New CAR-T therapies in South Korea to face stringent regulatory oversight, says GlobalData

South Korea has issued guidelines to monitor the side effects of the two approved CAR-T therapies – Kymriah (tisagenlecleucel) from Novartis and Carvykti (ciltacabtagene autoleucel) from Janssen. This will ensure a comprehensive database of adverse events including malignancies, if any in the local population, thereby ensuring patient safety in the country. However, regulatory focus on […]
Read more

Sanofi’s $140 million deal with Aqemia will accelerate drug discovery through AI, says GlobalData

In a new move within the pharmaceutical industry, Sanofi, a global pharmaceutical giant, has entered a monumental $140 million deal with Aqemia, a French pharmaceutical technology company. This collaboration aims to revolutionize drug discovery by leveraging Aqemia’s physics algorithms and generative artificial intelligence (AI), says GlobalData, a leading data and analytics company. Aqemia, built on […]
Read more

Madrigal’s efforts for resmetirom will set tone for future launches of NASH therapies, says GlobalData

Following the FDA’s acceptance of Madrigal Pharmaceuticals’ new drug application (NDA) and priority review for its THR-β agonist (resmetirom) in non-alcoholic steatohepatitis (NASH) in September 2023, the company has taken steps to fortify its leadership and financial position to gear up for the imminent launch of resmetirom. The measures initiated by Madrigal for the launch […]
Read more

Yuanruida gets first mover advantage in r/r B-cell ALL treatment in China, says GlobalData

CASI Pharmaceuticals and Juventas Cell Therapy recently received approval from China’s National Medical Products Administration (NMPA) for Yuanruida (Inaticabtagene Autoleucel/CNCT19), a domestic CD19-targeting CAR-T therapy for relapsed/refractory B-Cell Acute Lymphocytic Leukemia (r/r B-Cell ALL). The approval positions both companies as trailblazers in China’s dynamic oncology landscape and cell therapy.  As the first homegrown CAR-T to […]
Read more

Non-stimulants face uphill battle to penetrate ADHD market despite lower abuse potential, observes GlobalData

Stimulants, amphetamines, and methylphenidates continue to dominate the attention deficit hyperactivity disorder (ADHD) market across the seven major markets (7MM*), serving as the primary pharmacological treatment. Despite historical hesitancy towards their use in children, recent safety reassurances have increased acceptance. The late-stage pipeline introduces non-stimulant options with a focus on lower abuse potential. However, penetrating […]
Read more

Pharma contract manufacturing sees historic surge amidst inflation and investment challenges, reveals GlobalData

In the dynamic landscape of pharmaceutical contract manufacturing, the year 2022 witnessed unprecedented growth in revenues, marking the highest surge since 2011. The total commercial dose contract manufacturing organization (CMO) contract revenue year-on-year (YoY) soared by an impressive 8.4% in 2022. This growth, fueled by persistent high inflation, occurred amid the waning demand for COVID-19 […]
Read more

AbbVie’s $10.1 billion Immunogen deal fortifies oncology portfolio, signals big pharma’s ADC investment surge, says GlobalData

Following the news that AbbVie has agreed to buy biotech ImmunoGen , the maker of the FDA-approved ovarian cancer treatment Elahere, for $10.1 billion; Israel Stern, MSc,  Oncology & Hematology Analyst at GlobalData, a leading data and analytics company, offers his view: “The news comes one day after AbbVie announced that it is preparing to […]
Read more

China’s CAR-T cell therapy advancements still need to garner more attention from big pharma, says GlobalData

Chimeric Antigen Receptor- T (CAR-T) cell therapy, a revolutionary approach to treating certain types of cancer, has gained significant attention globally for its potential to transform cancer treatment paradigms. Although Western pharmaceutical companies were the first to develop CAR-T therapies, China has become a major force in the advancement of this innovative field in recent […]
Read more

Diagnosed prevalent cases of NASH to reach 26.55 million in 7MM by 2032, estimates GlobalData

The diagnosed prevalent cases of non-alcoholic steatohepatitis (NASH/MASH) in the seven major markets (7MM*) are projected to increase from 22.04 million in 2022 to 26.55 million in 2032, registering an annual growth rate (AGR) of 2.05%, according to GlobalData, a leading data and analytics company. GlobalData’s latest report: ‘Non-Alcoholic Steatohepatitis (NASH/MASH): Epidemiology Forecast to 2032’ […]
Read more

AstraZeneca’s oral GLP-1 combination for obesity and comorbidities to face increasingly competitive market, says GlobalData

AstraZeneca recently announced its strategy for the cardiometabolic market, in particular treating obesity and its comorbidities, by combining the glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy that the company recently acquired from Eccogene (ECC5004) with its cardio-metabolic therapies such as sodium-glucose co-transporter-2 (SGLT2) inhibitor Farxiga (dapagliflozin). The company intends to combine ECC5004 with treatments in its […]
Read more

World AMR Awareness Week 2023: Investment in novel therapies key priority, says GlobalData

World AMR Awareness Week (WAAW)* is observed on 18-24 November every year with the aim of improving awareness and understanding of antimicrobial resistance (AMR) and encouraging best practices for the responsible usage of antimicrobials. This year’s theme “Preventing antimicrobial resistance together” highlights the importance of cross-sectoral collaboration for tackling AMR. It serves as an important […]
Read more

Novo Nordisk targets to affirm superiority of CagriSema in obesity market, says GlobalData

Eli Lilly recently received FDA approval for Zepbound (tirzepatide), its glucagon-like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) dual agonist for patients with obesity. In response to Zepbound’s approval, Novo Nordisk launched a Phase III trial with the aim of proving the superiority of its pipeline combination therapy CagriSema as a weight loss drug over its active comparator, […]
Read more

Experts believe gene therapies will disrupt Gaucher disease drug market, says GlobalData

Following the conclusion of International Gaucher Disease Awareness Month, key opinion leaders (KOLs) interviewed by GlobalData believe pipeline gene therapies will significantly impact the Gaucher disease landscape. Gene therapy has the curative potential to provide patients with a healthy GBA1 copy, disrupting the Gaucher drug market. However, much groundwork remains to be covered, says GlobalData, […]
Read more
1 … 25 26 27 28 29 … 108